Akeso Biopharma, Inc.
Akeso Biopharma, Inc., a leading biopharmaceutical company headquartered in China, is at the forefront of innovative drug development. Founded in 2012, Akeso has rapidly established itself within the biotechnology industry, focusing on the research, development, and commercialisation of monoclonal antibodies and other biologics.
With a strong presence in major operational regions across Asia and beyond, Akeso is renowned for its unique portfolio of core products, including innovative therapies for oncology and autoimmune diseases. The company has achieved significant milestones, including successful clinical trials and partnerships that enhance its market position. Akeso's commitment to advancing healthcare through cutting-edge biopharmaceutical solutions underscores its reputation as a key player in the global biopharma landscape.
-20 vs industry average
Akeso Biopharma, Inc.’s score of 18 is lower than 11% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Akeso Biopharma, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Akeso Biopharma, Inc. yet.
Akeso Biopharma, Inc.'s reported carbon emissions
Akeso Biopharma, Inc., headquartered in China (CN), currently does not report any carbon emissions data, as indicated by the absence of specific figures in the available records. Consequently, there are no details regarding their Scope 1, Scope 2, or Scope 3 emissions.
Furthermore, Akeso Biopharma has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. This lack of data suggests that the company may still be in the early stages of developing its climate strategy or reporting framework.
As the biopharmaceutical industry increasingly prioritises sustainability, Akeso Biopharma's future climate commitments and emissions reporting will be crucial for aligning with global climate goals and enhancing transparency in their environmental impact.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Akeso Biopharma, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Akeso Biopharma, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Akeso Biopharma, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project